<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03992872</url>
  </required_header>
  <id_info>
    <org_study_id>EBSI-CV-317-002</org_study_id>
    <nct_id>NCT03992872</nct_id>
  </id_info>
  <brief_title>Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)</brief_title>
  <acronym>WRAIR</acronym>
  <official_title>A Phase 2 Open-label Study to Assess the Safety and Immunogenicity of an Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) in Prior Recipients of Other Alphavirus Vaccines Versus Alphavirus naïve Controls.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 parallel-group age- and gender-matched open label study in healthy adults&#xD;
      18-65 years of age to assess the safety and immunogenicity of an alum-adjuvanted chikungunya&#xD;
      virus-like particle vaccine (PXVX0317) in prior recipients of other alphavirus vaccines&#xD;
      versus alphavirus naïve controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is currently unknown whether prior exposure to heterologous alphaviruses will enhance or&#xD;
      interfere with immune responses to chikungunya virus (CHIKV) exposure or vaccination. The&#xD;
      objective of this study is to evaluate the safety and immunogenicity of the chikungunya&#xD;
      vaccine candidate PXVX0317 when administered to prior recipients of experimental alphavirus&#xD;
      vaccines versus alphavirus naïve gender and age-matched controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Actual">January 19, 2021</completion_date>
  <primary_completion_date type="Actual">January 19, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open Label Safety and immunogencity</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutralizing Antibody Response</measure>
    <time_frame>182 days</time_frame>
    <description>Evaluate the neutralizing antibody response to chikungunya virus induced by PXVX0317 when administered to prior alphavirus vaccine recipients versus gender- and age-matched controls</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chikungunya</condition>
  <arm_group>
    <arm_group_label>PXVX0317, a purified CHIKV VLP vaccine in Alhydrogel adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study participants will receive the same Investigational Product according to the same schedule. The alphavirus vaccine naïve subjects will serve as controls for determining the effect of pre-existing alphavirus immunity on vaccine safety and immunogenicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Chikungunya</intervention_name>
    <description>Virus Like Particle</description>
    <arm_group_label>PXVX0317, a purified CHIKV VLP vaccine in Alhydrogel adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 65 years old (inclusive)&#xD;
&#xD;
          -  For women of childbearing potential, a negative pregnancy test at screening and on&#xD;
             vaccination day, practicing highly effective contraception for at least 30 days prior&#xD;
             to vaccination, and willing to use a highly effective method of contraception through&#xD;
             study completion.&#xD;
&#xD;
          -  Able and willing to provide informed consent for study participation prior to&#xD;
             screening procedures.&#xD;
&#xD;
          -  Free of obvious health problems as established by medical history and clinical&#xD;
             examination at screening and enrollment.&#xD;
&#xD;
          -  Available to participate for the duration of the study (approximately 8 months).&#xD;
&#xD;
          -  For the cohort of prior alphavirus vaccine recipients, a documented history of prior&#xD;
             alphavirus vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute disease or febrile illness at the time of screening or enrollment.&#xD;
&#xD;
          -  Clinically significant cardiac, respiratory, rheumatologic or other medical or&#xD;
             psychiatric condition that, in the opinion of the Investigator, places the subject at&#xD;
             increased risk or affects their ability to understand and comply with study&#xD;
             procedures.&#xD;
&#xD;
          -  Abnormal screening lab test result that, in the opinion of the investigator, obscures&#xD;
             interpretation of the safety data or suggests a clinically significant cardiac,&#xD;
             respiratory, rheumatologic or other medical condition that places the subject at&#xD;
             increased risk.&#xD;
&#xD;
          -  Pregnant, lactating or planning to become pregnant during the study period.&#xD;
&#xD;
          -  Laboratory evidence of infection with Hepatitis B, C or HIV.&#xD;
&#xD;
          -  History of naturally (non-laboratory) acquired chikungunya or other alphavirus&#xD;
             infection or travel to a WHO-designated chikungunya-endemic region within 30 days&#xD;
             prior to Day 1.&#xD;
&#xD;
          -  History of acute allergic reaction to any component of CHIKV-VLP vaccine or&#xD;
             Alhydrogel®.&#xD;
&#xD;
          -  Current (30 days prior to Day 1) or anticipated use of systemic immunomodulatory or&#xD;
             immunosuppressive medications.&#xD;
&#xD;
          -  History of splenectomy, immunosuppressive condition, autoimmune disease, or&#xD;
             immunodeficient condition.&#xD;
&#xD;
          -  Family history of congenital or hereditary immunodeficiency.&#xD;
&#xD;
          -  Suspected or known current alcohol or drug abuse that, in the opinion of the&#xD;
             investigator, would interfere with the subject's ability to understand and comply with&#xD;
             study procedures.&#xD;
&#xD;
          -  Current intravenous drug use.&#xD;
&#xD;
          -  Prior receipt of an investigational chikungunya vaccine.&#xD;
&#xD;
          -  Receipt or planned receipt of any licensed vaccine from 30 days prior to Day 1 through&#xD;
             Day 29.&#xD;
&#xD;
          -  Participation in another clinical trial during the study period in which an&#xD;
             investigational product is administered.&#xD;
&#xD;
          -  For the cohort of alphavirus naïve vaccine recipients, history of prior alphavirus&#xD;
             vaccination is exclusionary.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McCarty, MD</last_name>
    <role>Study Director</role>
    <affiliation>Emergent BioSolutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>United States Army Medical Research Institute of Infectious Diseases</name>
      <address>
        <city>Fort Deterick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Institute of Research</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chikungunya Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT03992872/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

